News

Company and product news from BIOHIT HealthCare. Read all about our latest diagnostic tests for dyspepsia, inflammatory bowel disease and therapeutic drug monitoring here. Also find links to quality content of interest.

PANTS study published

Tuesday 26th Feb, 2019

PANTS Clinical Study published in THE LANCET Gastroenterology & Hepatology

The much anticipated prospective UK study aimed at investigating the mechanisms of anti-TNFa blocker treatment failure in patients with active luminal Crohn's disease has been published today in THE LANCET Gastroenterology and Hepatology. The 1610 patient study included inter alia therapeutic drug monitoring by measuring serum Drug Levels (Infliximab and Adalimumab) and Total Anti-drug antibodies to those drugs, in order to unveil risk factors for the prediction of primary non-response, non-remission and immunogenicity.

BIOHIT HealthCare appoints Exclusive Distributor in Ireland

Mon 21st Jan, 2019

BIOHIT products now available from AccuMed

BIOHIT HealthCare has signed an exclusive distribution agreement with AccuMed, an Irish company that specialises in the supply of Diagnostic tests to the Healthcare markets of Northern and Southern Ireland. The agreement grants exclusive rights to AccuMed for the sales and marketing of BIOHIT products to laboratories, endoscopy departments, pharmacies and clinics. With a strong focus on diagnostic tests and extensive knowledge of the gastroenterology market, our customers' needs will be met through excellent service from a local company.

IDKmonitor® Infliximab Drug Level ELISA has been recalibrated

Tues 8th Jan, 2019

New calibration now available plus standards and controls now Ready to use

Immundiagnostik AG, manufacturer of the lDKmonitor® lnfliximab drug level ELISA (K9655), have recalibrated the assay in accordance with the WHO standard material WHO infliximab standard (NlBSC, product #16/170). The recalibrated kit is available to order now and existing customers will be contacted about the change. To coincide with the recalibration, the kit calibrators and controls will switch from lyophilized to more convenient ready-to-use standards and controls. You can read more about the new NIBSC standard for Infliximab here: https://www.nibsc.org/documents/ifu/16-170.pdf If you have any questions about the assay please contact Customer Services on +44 151 550 4 550 or cs@biohithealthcare.co.uk and we will be happy to assist you.

New Therapeutic Drug Monitoring Assay

Tues 11th Dec, 2018

Ustekinumab Drug Levels in EDTA Plasma and Serum

IDKmonitor Ustekinumab Drug Level ELISA is now available exclusively from BIOHIT HealthCare. Ustekinumab (Stelara®) is a human monoclonal therapeutic antibody that targets the p40 subunit of IL-12 and 23. The drug is indicated for moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe Crohn's Disease via sub-cutaneous injection or intravenous infusion. The IDKmonitor Ustekinumab Drug Level ELISA (K9660) is for the determination and quantification of free therapeutic ustekinumab antibodies in EDTA plasma and serum samples.

 

Events

Check back soon!

Date(s)

to

ACB Scotland Spring 2020 Meeting

Cancelled

Date(s)

to

BSG Annual Meeting 2020

Postponed

Date(s)

to

Index

Contact Us

BIOHIT HealthCare Ltd

Pioneer House, Pioneer Business Park

North Road

Ellesmere Port

Cheshire CH65 1AD

United Kingdom

Tel: +44 151 550 4 550

Fax: +44 151 550 4 551

cs@biohithealthcare.co.uk

© 2020 BIOHIT HealthCare Ltd

  • Twitter Social Icon